Last Updated: September 28 2022

Piracetam is the parent compound of the racetam class of nootropic supplements. When supplemented, it provides a mild boost to brain function.

Piracetam is most often used for


Piracetam is the prototype for racetam supplements, which are a group of synthetic supplements intended to provide a cognitive boost.

Piracetam has a history of being used to treat cognitive impairment. According to a meta-analysis on human studies, piracetam improves general cognition when supplemented by people in a state of cognitive decline, such as the kind that comes with aging. Though piracetam may be a useful supplement for improving longevity, it offers limited benefits for healthy people.

Healthy people supplementing piracetam do experience little to no cognitive benefit. Though piracetam supplementation in healthy people is understudied, preliminary evidence suggests that piracetam is most effective for older people. Piracetam supplementation has also been found to reduce the chances of a breath-holding spell in children.

Piracetam enhances cellular membrane fluidity. This mechanism explains why piracetam is able to improve cognition, particularly in elderly people.

Piracetam is as effective as aspirin when it comes to preventing blood clotting, which makes it a useful supplemental intervention after cardiovascular trauma.

What else is Piracetam known as?
Note that Piracetam is also known as:
  • Pyracetam
  • Pyrrolidone acetamide
  • 2-Oxo-1-pyrrolidine
  • Memotopril
  • Fezam (with cinnarizine)
  • UCB6215
Dosage information

The standard piracetam dose for children is between 40-100mg per kilogram of bodyweight. This dose is intended for the treatment of breath-holding spells, though it has also been used for children with dyslexia. The lower end of the range (40-50mg/kg) is used most often.

The standard piracetam dose for adults is between 1,200-4,800mg a day. The largest effective dose is 1,600mg, taken three times a day for a total of 4,800mg.

Supplements Demystified: Get Our Unbiased, Evidence-Based Guide

Examine Database: Piracetam
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

3.^Dimond SJ, Scammell RE, Pryce IG, Huws D, Gray CSome effects of piracetam (UCB 6215, Nootropyl) on chronic schizophreniaPsychopharmacology (Berl).(1979 Sep)
5.^Tilborg A, Jacquemin D, Norberg B, Perpète E, Michaux C, Wouters JStructural study of piracetam polymorphs and cocrystals: crystallography redetermination and quantum mechanics calculationsActa Crystallogr B.(2011 Dec)
7.^Tacconi MT, Wurtman RJPiracetam: physiological disposition and mechanism of actionAdv Neurol.(1986)
8.^Rameis H, Hitzenberger G, Kutscher R, Manigley CPharmacokinetics of piracetam: a study on the bioavailability with special regard to renal and non-renal eliminationInt J Clin Pharmacol Ther.(1994 Sep)
12.^Heiss WD, Hebold I, Klinkhammer P, Ziffling P, Szelies B, Pawlik G, Herholz KEffect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomographyJ Cereb Blood Flow Metab.(1988 Aug)
14.^Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Müller WEPiracetam improves mitochondrial dysfunction following oxidative stressBr J Pharmacol.(2006 Jan)
15.^Copani A, Genazzani AA, Aleppo G, Casabona G, Canonico PL, Scapagnini U, Nicoletti FNootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal culturesJ Neurochem.(1992 Apr)
19.^Solntseva EI, Bukanova JV, Ostrovskaya RU, Gudasheva TA, Voronina TA, Skrebitsky VGThe effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channelsGen Pharmacol.(1997 Jul)
20.^Bravo-Martínez J, Arenas I, Vivas O, Rebolledo-Antúnez S, Vázquez-García M, Larrazolo A, García DEA novel CaV2.2 channel inhibition by piracetam in peripheral and central neuronsExp Biol Med (Maywood).(2012 Oct 1)
21.^Lukyanetz EA, Shkryl VM, Kostyuk PGSelective blockade of N-type calcium channels by levetiracetamEpilepsia.(2002 Jan)
22.^Winnicka K, Tomasiak M, Bielawska APiracetam--an old drug with novel properties?Acta Pol Pharm.(2005 Sep-Oct)
23.^Gouliaev AH, Senning APiracetam and other structurally related nootropicsBrain Res Brain Res Rev.(1994 May)
25.^Müller WE, Koch S, Scheuer K, Rostock A, Bartsch REffects of piracetam on membrane fluidity in the aged mouse, rat, and human brainBiochem Pharmacol.(1997 Jan 24)
26.^Eckert GP, Cairns NJ, Müller WEPiracetam reverses hippocampal membrane alterations in Alzheimer's diseaseJ Neural Transm.(1999)
28.^Müller WE, Eckert A, Kurz C, Eckert GP, Leuner KMitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspectsMol Neurobiol.(2010 Jun)
29.^Leuner K, Hauptmann S, Abdel-Kader R, Scherping I, Keil U, Strosznajder JB, Eckert A, Müller WEMitochondrial dysfunction: the first domino in brain aging and Alzheimer's diseaseAntioxid Redox Signal.(2007 Oct)
31.^Maillis A, Karayanidis F, Koutsoukos E, Angelopoulos E, Stefanis CEffects of piracetam on single central neuronsNeuropsychobiology.(1988)
32.^Dimond SJ, Brouwers EMIncrease in the power of human memory in normal man through the use of drugsPsychopharmacology (Berl).(1976 Sep 29)
33.^Wilsher C, Atkins G, Manfield PPiracetam as an aid to learning in dyslexia. Preliminary reportPsychopharmacology (Berl).(1979 Sep)
34.^Mindus P, Cronholm B, Levander SE, Schalling DPiracetam-induced improvement of mental performance. A controlled study on normally aging individualsActa Psychiatr Scand.(1976 Aug)
35.^Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad BClinical efficacy of piracetam in cognitive impairment: a meta-analysisDement Geriatr Cogn Disord.(2002)
36.^Flicker L, Grimley Evans GPiracetam for dementia or cognitive impairmentCochrane Database Syst Rev.(2001)
38.^Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine FPiracetam in elderly psychiatric patients with mild diffuse cerebral impairmentPsychopharmacology (Berl).(1983)
41.^Abuzzahab FS Sr, Merwin GE, Zimmermann RL, Sherman MCA double blind investigation of piracetam (Nootropil) vs placebo in geriatric memoryPharmakopsychiatr Neuropsychopharmakol.(1977 Mar)
43.^Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon MLong-term and high-dose piracetam treatment of Alzheimer's diseaseNeurology.(1993 Feb)
44.^Batysheva TT, Bagir' LV, Kostenko EV, Artemova IY, Vdovichenko TV, Ganzhula PA, Zhuravleva EY, Ismailov AM, Lisenker LN, Nesterova OV, Otcheskaya OV, Rotor LD, Khozova AA, Boiko ANExperience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disordersNeurosci Behav Physiol.(2009 Feb)
46.^Wilsher CREffects of piracetam on developmental dyslexiaInt J Psychophysiol.(1986 May)
47.^Fedi M, Reutens D, Dubeau F, Andermann E, D'Agostino D, Andermann FLong-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsyArch Neurol.(2001 May)
49.^Uebelhack R, Vohs K, Zytowski M, Schewe HJ, Koch C, Konertz WEffect of piracetam on cognitive performance in patients undergoing bypass surgeryPharmacopsychiatry.(2003 May)
50.^Holinski S, Claus B, Alaaraj N, Dohmen PM, Kirilova K, Neumann K, Uebelhack R, Konertz WCerebroprotective effect of piracetam in patients undergoing coronary bypass burgeryMed Sci Monit.(2008 Nov)
51.^Holinski S, Claus B, Alaaraj N, Dohmen PM, Neumann K, Uebelhack R, Konertz WCerebroprotective effect of piracetam in patients undergoing open heart surgeryAnn Thorac Cardiovasc Surg.(2011)
52.^Szalma I, Kiss A, Kardos L, Horváth G, Nyitrai E, Tordai Z, Csiba LPiracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placeboAnn Thorac Surg.(2006 Oct)
53.^Ricci S, Celani MG, Cantisani TA, Righetti EPiracetam in acute stroke: a systematic reviewJ Neurol.(2000 Apr)
57.^Szelies B, Mielke R, Kessler J, Heiss WDRestitution of alpha-topography by piracetam in post-stroke aphasiaInt J Clin Pharmacol Ther.(2001 Apr)
58.^Kampman K, Majewska MD, Tourian K, Dackis C, Cornish J, Poole S, O'Brien CA pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependenceAddict Behav.(2003 Apr)
59.^Navarro SA, Serafim KG, Mizokami SS, Hohmann MS, Casagrande R, Verri WA JrAnalgesic activity of piracetam: effect on cytokine production and oxidative stressPharmacol Biochem Behav.(2013 Apr)
60.^Mattie-Luksic M, Javornisky G, DiMario FJAssessment of stress in mothers of children with severe breath-holding spellsPediatrics.(2000 Jul)
61.^DiMario FJ JrBreath-holding spells in childhoodAm J Dis Child.(1992 Jan)
62.^Winnicka K, Tomasiak M, Bielawska APiracetam--an old drug with novel propertiesActa Pol Pharm.(2005 Sep-Oct)
65.^Azam M, Bhatti N, Shahab NPiracetam in severe breath holding spellsInt J Psychiatry Med.(2008)
67.^Lukkarinen H, Virtanen I, Arikka H, Arola A, Peltola M, Ekblad HRecurrent sinus arrest and asystole due to breath-holding spell in a toddler; recovery with levetiracetam-therapyCirculation.(2010 Dec 21)
68.^Vural M, Ozekmekçi S, Apaydin H, Altinel AHigh-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophyMov Disord.(2003 Apr)
71.^Stockmans F, Deberdt W, Nyström A, Nyström E, Stassen JM, Vermylen J, Deckmyn HInhibitory effect of piracetam on platelet-rich thrombus formation in an animal modelThromb Haemost.(1998 Jan)
72.^Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys CPlatelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjectsArzneimittelforschung.(1993 Feb)
74.^Evers S, Grotemeyer KHPiracetam and platelets--a review of laboratory and clinical dataPharmacopsychiatry.(1999 Mar)
77.^Keeble JE, Bodkin JV, Liang L, Wodarski R, Davies M, Fernandes ES, Coelho Cde F, Russell F, Graepel R, Muscara MN, Malcangio M, Brain SDHydrogen peroxide is a novel mediator of inflammatory hyperalgesia, acting via transient receptor potential vanilloid 1-dependent and independent mechanismsPain.(2009 Jan)
78.^Ndengele MM, Cuzzocrea S, Esposito E, Mazzon E, Di Paola R, Matuschak GM, Salvemini DCyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivityFASEB J.(2008 Sep)
79.^Wang ZQ, Porreca F, Cuzzocrea S, Galen K, Lightfoot R, Masini E, Muscoli C, Mollace V, Ndengele M, Ischiropoulos H, Salvemini DA newly identified role for superoxide in inflammatory painJ Pharmacol Exp Ther.(2004 Jun)
80.^Leung L, Cahill CMTNF-alpha and neuropathic pain--a reviewJ Neuroinflammation.(2010 Apr 16)
81.^Psillas G, Pavlidis P, Karvelis I, Kekes G, Vital V, Constantinidis JPotential efficacy of early treatment of acute acoustic trauma with steroids and piracetam after gunshot noiseEur Arch Otorhinolaryngol.(2008 Dec)
83.^Mondadori C, Bhatnagar A, Borkowski J, Häusler AInvolvement of a steroidal component in the mechanism of action of piracetam-like nootropicsBrain Res.(1990 Jan 1)
85.^Häusler A, Persoz C, Buser R, Mondadori C, Bhatnagar AAdrenalectomy, corticosteroid replacement and their importance for drug-induced memory-enhancement in miceJ Steroid Biochem Mol Biol.(1992 Mar)
88.^Mondadori C, Ducret T, Häusler AElevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimeticsPsychopharmacology (Berl).(1992)
89.^Mondadori C, Petschke FDo piracetam-like compounds act centrally via peripheral mechanismsBrain Res.(1987 Dec 1)
91.^Wurtman RJ, Magil SG, Reinstein DKPiracetam diminishes hippocampal acetylcholine levels in ratsLife Sci.(1981 Mar 9)
94.^Platel A, Jalfre M, Pawelec C, Roux S, Porsolt RDHabituation of exploratory activity in mice: effects of combinations of piracetam and choline on memory processesPharmacol Biochem Behav.(1984 Aug)
95.^Bartus RT, Dean RL 3rd, Sherman KA, Friedman E, Beer BProfound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged ratsNeurobiol Aging.(1981 Summer)
96.^Borges MM, Paula-Barbosa MM, Volk BChronic alcohol consumption induces lipofuscin deposition in the rat hippocampusNeurobiol Aging.(1986 Sep-Oct)
97.^Brandão F, Paula-Barbosa MM, Cadete-Leite APiracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intakeAlcohol.(1995 May-Jun)
98.^Brandão F, Cadete-Leite A, Andrade JP, Madeira MD, Paula-Barbosa MMPiracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcoholAlcohol.(1996 May-Jun)
99.^Boĭko AN, Kabanov AA, Es'kina TA, Sheliakina LA, Shchukin AI, Batysheva TT, Artemova IIu, Vdovichenko TV, Volovets SA, Ganzhula PAPhezam efficacy in patients with chronic cerebral ischemic diseaseZh Nevrol Psikhiatr Im S S Korsakova.(2005)
100.^Arabkhanova MA, Pyshkina LI, Kabanov AA, Kolesnikova TI, Iasamanova AN, Martynov MIu, Gusev EIPhezam in combined therapy of ischemic strokeZh Nevrol Psikhiatr Im S S Korsakova.(2008)
101.^Nikolova M, Nikolov R, Milanova DAnti-hypoxic effect of piracetam and its interaction with prostacyclinMethods Find Exp Clin Pharmacol.(1984 Jul)
102.^Nikolov R, Nikolova M, Milanova DStudy on the anti-hypoxic effect of cinnarizine and its interaction with prostacyclinMethods Find Exp Clin Pharmacol.(1984 Mar)
104.^Ojha R, Sahu AN, Muruganandam AV, Singh GK, Krishnamurthy SAsparagus recemosus enhances memory and protects against amnesia in rodent modelsBrain Cogn.(2010 Oct)
105.^Rai KS, Murthy KD, Karanth KS, Rao MSClitoria ternatea (Linn) root extract treatment during growth spurt period enhances learning and memory in ratsIndian J Physiol Pharmacol.(2001 Jul)
106.^Wattanathorn J, Jittiwat J, Tongun T, Muchimapura S, Ingkaninan KZingiber officinale Mitigates Brain Damage and Improves Memory Impairment in Focal Cerebral Ischemic RatEvid Based Complement Alternat Med.(2011)
108.^Giurgea MPiracetam: toxicity and reproduction studiesFarmaco Prat.(1977 Jan)
109.^De Reuck J, Van Vleymen BThe clinical safety of high-dose piracetam--its use in the treatment of acute strokePharmacopsychiatry.(1999 Mar)